IMR Press / CEOG / Volume 34 / Issue 3 / pii/2007040

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss

Show Less
1 2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieion Hospital 'Hematology Laboratory, Evangelismos General Hospital, Athens (Greece)
Clin. Exp. Obstet. Gynecol. 2007, 34(3), 143–145;
Published: 10 September 2007

Purpose: To assess the safety and efficacy of tinzaparin sodium for the management of recurrent pregnancy loss. Methods: The study included 62 women with a history of recurrent pregnancy loss and at least one factor of thrombophilic disorder. Of these, 31 received 50 IU/kg of tinzaparin sodium daily (Group A), and 33 received 100 mg of aspirin daily (Group B). Results: Group A sub­jects (receiving tinzaparin sodium) had six new abortions, whereas Group B subjects (receiving aspirin) had 11 (significant differ­ence). Cases of intrauterine growth restriction (none in Group A and 2 in Group B), placental abruption (one in Group A and 4 in Group B), and preeclampsia (one in Group A and 3 in Group B) were comparable between the two groups. Finally coagulation dis­orders (none in Group A and 6 in Group B) were significantly fewer in Group A. Conclusion: A 50 IU/kg daily dose of tinzaparin sodium seems to be effective for the management of recurrent abortion and has high standards of safety.

Recurrent pregnancy Joss
Low molecular weight heparin
Tinzaparin sodium
Back to top